On September 29, IMPACT THERAP-B rose 8.26% in regular trading, reaching HKD 14.03 before trading at HKD 14.17, with turnover of HKD 62.75 million. The stock staged a rebound after a prior pullback of over 10%.

The rally was driven by the continued positive impact of the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issuing a favorable opinion recommending marketing authorization for Senaparib (Sepalna) as a first-line maintenance therapy for advanced epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. The application will now proceed to the European Commission for a final legally binding decision. If approved, Senaparib will be authorized for sale across all EU member states and European Economic Area countries.

Additionally, the company previously secured an exclusive licensing agreement with Pharmanovia covering Europe, the Middle East, North Africa, Australia, and New Zealand, with total deal consideration of up to EUR 423.5 million. The company also reported strong first-half revenue of RMB 105 million, up 316.8% year-over-year, while its adjusted net loss narrowed by 62.6%. Its H shares were included in the Stock Connect program effective September 7, broadening access for mainland investors.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)